Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616995 | 0.86 | BTN3A1 (0.32) | BTN3A1 | |
| SCHEMBL2763848 | 0.86 | BTN3A1 (0.32) | BTN3A1 | |
| SCHEMBL10679170 | 0.86 | BTN3A1 (0.32) | BTN3A1 | |
| SCHEMBL4659598 | 0.83 | NOS1 (0.32) | NOS1NOS3NOS2BTN3A1 | |
| SCHEMBL10314812 | 0.81 | NOS3 (0.38) | NOS1NOS3NOS2KMT2ASLC7A5 | |
| SCHEMBL21224417 | 0.81 | — | — | |
| SCHEMBL20591675 | 0.81 | NOS3 (0.38) | NOS1NOS3NOS2KMT2ASLC7A5 | |
| SCHEMBL21224419 | 0.81 | — | — | |
| SCHEMBL27350841 | 0.81 | NOS1 (0.36) | NOS1NOS3NOS2LTA4HLMNA | |
| SCHEMBL2089179 | 0.78 | TDP1 (0.35) | BTN3A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090047247-A1 | Pyrrolidine Derivatives | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326019-A1 | 3,4-BICYCLIC PYRROLIDINE ANTIVIRALS | ZC3HAV1, EIF2AK2, POLRMT | NOS1 947/4885NOS3 418/4885NOS2 1044/4885 |
| US-20090060874-A1 | BICYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, ZC3HAV1, POLRMT | NOS1 967/4885NOS3 794/4885NOS2 846/4885 |
| US-20090047247-A1 | Pyrrolidine Derivatives | ZC3HAV1, EIF2AK2, POLRMT | NOS1 474/4885NOS3 449/4885NOS2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.